Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-22-Speech-1-173"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-11-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Information on medicinal products (Community code relating to medicinal products) - Information on medicinal products (Community procedures for the authorisation and supervision of medicinal products) (debate)2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20101122.17.1-173"2
lpv:hasSubsequent	lp_eu:2010-11-22-Speech-1-1742
lpv:speaker	lp:Oreste Rossi2
lpv:spokenAs	member; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2012-02-01)3 member; ENVI (2009-07-16--2012-01-18)3 substitute; BUDG (2009-10-07--2012-01-18)3 substitute; IMCO (2009-07-16--2012-01-18)3 unknown; Lega Nord (2009-07-14--2013-03-14)3 member; Delegation for relations with Japan (2009-09-16--2012-02-14)3 member; EFD (2009-07-14--2013-06-11)3
lpv:translated text	"Madam President, ladies and gentlemen, we believe that the regulation is positive, since it is aimed at providing a harmonised legislative framework with regard to non-promotional information on prescription medicines which pharmaceutical companies may communicate to the public, leaving the advertising ban unchanged. The motion stresses the difference between advertising and information. The provision of information is based on the principles of active research. Doctors must continue to be the main source of information on medicinal products. Other sources, which are understood to be complementary and which include magazines and newspapers, should be maintained. The central focus is the patient’s right to information, with the active participation of organisations that represent citizens, particularly patients. We voted in favour."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph